Opus Genetics Reports Positive Data From Two Gene Therapy Programs
In the initial low-dose Cohort 1 of its Phase 1/2 trial, OPGx-BEST1 improved retinal sensitivity in 75% of evaluable participants. The company also reported new analyses linking BEST1 retinal structure to visual function.
Story updates
08:01:43 PM UTC
SquawkNews
Opus Genetics reported Phase 1/2 OPGx-BEST1 data with retinal sensitivity gains in 3 of 4 evaluable patients and Phase 1/2/3 OPGx-LCA5 data showing sustained adult improvements to 24 months; Phase 3 OPGx-LCA5 dosing is expected in Q4 2026.Material DetailsContext by AI AnalystThis is mid-stage clini…